Next Article in Journal
The Efficacy of Re-Warm-Up Practices during Half-Time: A Systematic Review
Previous Article in Journal
ABCA1 rs1883025 and CYP4F2 rs2108622 Gene Polymorphism Association with Age-Related Macular Degeneration and Anti-VEGF Treatment
Previous Article in Special Issue
The “Undetermined Significance” of 18F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)
Case Report

Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach

1
Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy
2
Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
3
Division of Pathology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Konstantinos Dimas
Received: 5 August 2021 / Revised: 9 September 2021 / Accepted: 14 September 2021 / Published: 17 September 2021
(This article belongs to the Special Issue 2-[18F]-FDG PET/CT in Oncology: New Evidences and Future Perspectives)
Here we report the case of concomitant favorable-risk prostate cancer and Hodgkin Lymphoma in a 38-year old male. 68Ga-Prostate Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography (68Ga-PSMA-11 PET/CT) was performed for staging purposes, showing the focal PSMA prostatic uptake as well as the presence of enlarged low-PSMA expressing mediastinal lymphadenopathies, thus raising the suspicion of another malignancy. A subsequent 18F-Fluorodeoxyglucose (18F-FDG) PET/CT demonstrated a high FDG-avidity by mediastinal lymphadenopathies as opposed to the low prostate cancer FDG uptake. Of note, both tumor entities were clearly detected by the two scans. However, different ranges in terms of Maximum Standardized Uptake Value (SUVmax) uptake allowed the discrimination between the two tumor entities. At the subsequent mediastinal lymph nodal biopsy, the coexistence of Hodgkin lymphoma was documented. The present case suggests that even if specific for prostate cancer, 68Ga-PSMA-11 PET/CT may raise the suspicion of other concurrent malignancies thanks to its non-receptor bounding mechanism. Further, it shows that in certain cases, the combination of 18F-FDG and 68Ga-PSMA PET/CT imaging may non-invasively guide the clinical management, optimizing the diagnostic process and the subsequent therapeutic interventions. View Full-Text
Keywords: PSMA PET/CT; FDG PET/CT; prostate cancer; Hodgkin lymphoma PSMA PET/CT; FDG PET/CT; prostate cancer; Hodgkin lymphoma
Show Figures

Figure 1

MDPI and ACS Style

Miceli, A.; Riondato, M.; D’Amico, F.; Donegani, M.I.; Piol, N.; Mora, M.; Spina, B.; Morbelli, S.; Bauckneht, M. Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach. Medicina 2021, 57, 975. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57090975

AMA Style

Miceli A, Riondato M, D’Amico F, Donegani MI, Piol N, Mora M, Spina B, Morbelli S, Bauckneht M. Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach. Medicina. 2021; 57(9):975. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57090975

Chicago/Turabian Style

Miceli, Alberto, Mattia Riondato, Francesca D’Amico, Maria I. Donegani, Nataniele Piol, Marco Mora, Bruno Spina, Silvia Morbelli, and Matteo Bauckneht. 2021. "Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET/CT Approach" Medicina 57, no. 9: 975. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57090975

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop